These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19195630)

  • 1. Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis.
    Mallat A; Lotersztajn S
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):680-4. PubMed ID: 19195630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoids and their role in fatty liver disease.
    Mallat A; Lotersztajn S
    Dig Dis; 2010; 28(1):261-6. PubMed ID: 20460921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cannabinoids in the development of fatty liver (steatosis).
    Purohit V; Rapaka R; Shurtleff D
    AAPS J; 2010 Jun; 12(2):233-7. PubMed ID: 20204561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
    Fride E
    Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Peripheral Cannabinoid Receptor Type 1 (CB
    O'Sullivan SE; Yates AS; Porter RK
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cannabinoids on immunoreactivity of regulatory peptides, produced in rat thyroid C cells; preliminary investigations.
    Sawicki B; Zbucki RL; Hryniewicz A; Kosiorek P; Bialuk I; Winnicka MM; Dadan J
    Rocz Akad Med Bialymst; 2004; 49 Suppl 1():143-5. PubMed ID: 15638402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the CB1 receptor in the regulation of sleep.
    Murillo-Rodríguez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1420-7. PubMed ID: 18514375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
    Suhara Y; Oka S; Kittaka A; Takayama H; Waku K; Sugiura T
    Bioorg Med Chem; 2007 Jan; 15(2):854-67. PubMed ID: 17110113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
    Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
    Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anandamide receptor signal transduction.
    Goodfellow CE; Glass M
    Vitam Horm; 2009; 81():79-110. PubMed ID: 19647109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
    Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
    Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.
    Talwar R; Potluri VK
    CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):536-44. PubMed ID: 21631407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The orphan receptor GPR55 is a novel cannabinoid receptor.
    Ryberg E; Larsson N; Sjögren S; Hjorth S; Hermansson NO; Leonova J; Elebring T; Nilsson K; Drmota T; Greasley PJ
    Br J Pharmacol; 2007 Dec; 152(7):1092-101. PubMed ID: 17876302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid mechanisms of pain suppression.
    Walker JM; Hohmann AG
    Handb Exp Pharmacol; 2005; (168):509-54. PubMed ID: 16596786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B.
    Dai E; Zhang L; Ye L; Wan S; Feng L; Qi Q; Yao F; Li Z
    Int J Infect Dis; 2017 Jun; 59():124-130. PubMed ID: 28315398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.